Eisai Co., Ltd., a leading global research and development─based pharmaceutical company, announced that the latest information on its in─house discovered and developed anticancer agent eribulin mesylate
More From BioPortfolio on "Eisai to present new research on anticancer agent eribulin at 41st SABC symposium"